The filing covers the sale of the clinical stage biotechnology company's common stock, preferred stock, debt securities, warrants and units.
Unless specified in a prospectus supplement, the company plans to use the net proceeds from the sale of securities for general corporate purposes.
Price: 12.89, Change: -0.08, Percent Change: -0.62
|Wells Fargo Adjusts Price Target on Celanese to $180...|
|Wells Fargo Adjusts Carnival's Price Target to $13 F...|
|Stifel Adjusts Carnival's Price Target to $20 From $...|
|Waldencast Acquisition Enters Agreement for $225 Mil...|
|Stocks Set to Build on Gains as Futures Advance Pre-...|